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Abstract
Cutaneous melanoma is a lethal malignancy that arises spontaneously or via in situ precursor neoplasms. While melanoma
in situ and locally invasive malignant melanoma can be cured surgically, these lesions can sometimes be difficult to
distinguish from melanocytic nevi. Thus, the identification of histolopathologic or molecular features that distinguish these
biologically distinct lesions would represent an important advance. To this end, we determined the abundance of
melanocytic primary cilia in a series of 62 cases composed of typical cutaneous melanocytic nevi, melanoma in situ, invasive
melanoma, and metastatic melanoma. Primary cilia are sensory organelles that modulate developmental and adaptive
signaling and notably, are substantially depleted from the neoplastic epithelium of pancreatic carcinoma at a stage
equivalent to melanoma in situ. In this series, we find that while nearly all melanocytes in 22 melanocytic nevi possessed a
primary cilium, a near-complete loss of this organelle was observed in 16 cases of melanoma in situ, in 16 unequivocal
primary invasive melanomas, and in 8 metastatic tumors, each associated with a cutaneous primary lesion. These findings
suggest that the primary cilium may be used to segregate cutaneous invasive melanoma and melanoma in situ from
melanocytic nevi. Moreover, they place the loss of an organelle known to regulate oncogenic signaling at an early stage of
melanoma development.
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Introduction
Melanoma accounts for approximately 4% of skin neoplasms
but 80-90% of skin cancer deaths. While the prognosis of
disseminated melanoma is bleak, prospects for the cure of locally
invasive and in situ melanoma by surgical approaches are
excellent. Thus, improved recognition and understanding of the
key biological steps that initiate melanomagenesis are critical.
However, early stage melanomas can at times be challenging to
distinguish morphologically from melanocytic nevi, which are
also known aspigmented moles. Accordingly, diagnostic discor-
dance rates as high as 25% have been reported when case series
have been reviewed by multiple pathologists [1,2]. Moreover,
because between 1 and 2 million biopsies are performed each
year to evaluate for melanoma and there exist strong
medicolegal incentives to overdiagnose this malignancy, a
substantive cost-burden is placed on the heath care system and
many patients are subjected to unnecessary treatment, surgical
procedures, and disease monitoring. Conversely, missed mela-
noma diagnoses result in preventable morbidity and mortality.
Thus, the continued development of ancillary testing modalities
able to identify early events in melanomagenesis is a high
priority.
Primary cilia are ubiquitous sensory organelles that coordinate
adaptive and developmental signaling by recruiting, organizing,
and mobilizing diverse classes of signaling molecules in response to
extracellular ligands [3]. Indeed, the growing list of receptors
known to localize to primary cilia includes those of the Hedgehog,
Wnt, somatostatin, serotonin, PDGF, and EGF signaling pathways
[4]. Structurally, the primary cilium is composed of a 9+0
microtubular axoneme ensheathed by a membrane that is
contiguous with, but biochemically distinct from, the plasma
membrane [5]. The microtubule doublets of the ciliary axoneme
are assembled atop and continuous with two of the three triplet
microtubules of the maternal centriole. Thus, primary cilia are
always found in association with a maternal centriole. Moreover,
because ciliary tubulins undergo extensive post-translational
modification, antibodies directed towards modified tubulins,
including acetylated, polyglutamylated, and detyrosinated forms,
can be used in conjunction with antibodies recognizing centriolar
proteins to identify primary cilia with a high degree of specificity
[6,7].
Defects in primary cilium assembly and function are associated
with profound developmental disorders including Bardet Biedl
Syndrome, Alstrom Syndrome, and polycystic kidney disease [8].
However, relationships between this organelle, its associated
transport machinery, and cancer are just beginning to be explored.
In the first thorough study of the fate of this organelle during
cancer development, we found that primary cilium assembly is
actively suppressed by excessive Kras signaling in nearly all
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ma development, beginning with the appearance of its major in
situ neoplasm [6]. However, more recent studies have shown
variable frequencies of occurrence of primary cilia amongst the
neoplastic cells of basal cell carcinoma, medulloblastoma, and
renal carcinoma [9-11]. More historical accounts demonstrate that
pituitary adenocarcinomas and ovarian Brenner tumors are
ciliated and, indeed, there are examples in which cells appear to
have acquired, rather than lost, the ability to ciliate following
transformation [12]. Overall, the variation in the behavior of the
primary cilium that follows neoplastic transformation may reflect
variable requirements for the organelle in the oncogenic signaling
pathways recruited by particular tumors and/or the particular cell
type that has become transformed.
Interestingly however, pancreatic ductal adenocarcinoma and
cutaneous melanoma have similar genetics, both exhibiting
increased incidence in kindreds bearing heritable p16
Ink4a and
other mutations. Moreover, melanoma and pancreatic ductal
adenocarcinoma are frequently driven by activating mutations in
components of the Ras signaling pathway [13–16] and we have
shown that excessive Ras signaling can actively suppress cilium
assembly in pancreatic ductal adenocarcinoma cells [6]. There-
fore, because primary cilia frequently appear on normal
cutaneous melanocytes [17,18], we sought to determine whether
a pattern of cilium loss analogous to that seen in pancreatic
carcinoma development might permit the segregation of
cutaneous melanoma and melanocytic nevi. In this study, we
quantitated melanocytic primary cilia in a series of 62 cutaneous
cases composed of typical melanocytic nevi, melanoma in situ,
invasive melanoma, and metastatic melanoma of known cutane-
ous origin.
Results
To identify differences in the ciliation status of melanocytes
present in distinct melanocytic lesions, we collected 22 cases of
melanocytic nevi, 16 cases of melanoma in situ, and 16 cases of
invasive melanoma and subjected them to immunofluorescence
microscopy. These specimens were costained with antibodies
directed towards Sox10, to detect melanocytes [19,20], acetylated
or detyrosinated alpha tubulin, to detect the modified tubulins of
the ciliary axoneme [21,22], and gamma tubulin or CP110, to
detect centrioles and basal bodies [23]. To assess the abundance of
primary cilia, we considered any elongated acetylated or
detyrosinated tubulin -containing structure in association with
CP110 or a gamma tubulin -positive puncta to be a primary
cilium. Because cytoplasmic microtubules can also contain
modified tubulins [21,22], this consideration ensured that primary
cilia, and not cytoplasmic microtubules, were counted. Because
tubulin acetylation is not obligate for axoneme assembly [24], it
was also important to utilize multiple markers of the ciliary
axoneme. Finally, because centriolar microtubules can also
contain modified tubulins [25], we considered acetylated or
detyrosinated tubulin puncta to represent centrioles and not
primary cilia, though we appreciate that such structures may in
fact represent extremely short ciliary axonemes. Nevertheless, this
strategy was sufficient to identify unequivocal differences in the
ciliation status of melanocytes present in the distinct types of
lesions under study here.
When examined by immunofluorescence microscopy, we found
that an average of 94% (range: 91% - 100%; SD: 3.06) of the
Sox10 -positive melanocytes present in any of the 22 melanocytic
nevi examined bore a primary cilium (figures 1 and S2). Identical
Figure 1. Primary cilia are retained by the melanocytes of typical compound and junctional cutaneous melanocytic nevi.
Immunostaining as indicated. (A and B) Low-power images of cutaneous melanocytic nevi stained with hematoxylin and eosin (A) or for
immunofluorescence microscopy (B). Scale bars: 100 mm. (C) Split image of nested melanocytes within a melanocytic nevus. Sox10 epifluorescence
has been omitted from the right half of the image to enhance visualization of cilia and centriole staining. Scale bar: 50 mm. (D) High power image of
nest shown in panel C. Scale bar: 25 mm.
doi:10.1371/journal.pone.0027410.g001
Cilium Loss during Melanoma Development
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27410Figure 2. Melanocytes in melanoma in situ frequently fail to possess a primary cilium. Immunostaining as indicated. (A and B) Low-power
images of cutaneous melanoma in situ stained with hematoxylin and eosin (A) or for immunofluorescence microscopy (B). Scale bars: 100 mm. (C)
Melanoma in situ cells. Scale bar: mm. (D) High power image of melanoma. Upper inset: Sox10 positive melanoma in situ cell showing absence of
ciliated centrioles. Lower inset: Sox10 negative cell with ciliated centriole.
doi:10.1371/journal.pone.0027410.g002
Figure 3. Melanocytes in invasive melanoma frequently fail to possess a primary cilium. Immunostaining as indicated. (A and B) Low-
power images of invasive cutaneous melanoma stained with hematoxylin and eosin (A) or for immunofluorescence microscopy (B). Scale bars:
100 mm. (C) Invasive melanoma cells. Scale bar: 50 mm. (D) High power image of invasive melanoma. Upper inset: Invasive melanoma cell showing
absence of ciliated centrioles.
doi:10.1371/journal.pone.0027410.g003
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acetylated tubulin antibodies were utilized (figure S1). We also
identified primary cilia on non-melanocytic Sox10 -negative cells
in regions adjacent to the melanocytic nevi in each specimen (not
shown). In contrast, when dermal lymphocytes and other
leukocyte populations were examined, detyrosinated and acetylat-
ed tubulin positive centrioles were observed but never a primary
cilium, a finding consistent with the fact that leukocytes as a class
have never been observed to ciliate (not shown). Together, these
findings highlight the specificity of our staining and scoring system
and demonstrate that benign melanocytes are ciliated.
We next examined a set of 32 cutaneous melanocytic
proliferations comprised of 16 cases of cutaneous melanoma in
situ and 16 primary invasive malignant melanomas. As seen in
melanocytic nevi, we observed ciliated Sox10-negative cells
(figure 2D, lower inset) and non-ciliated leukocytes (not shown)
in all 16 cases, providing an internal positive control for each
specimen. In contrast however, an average of 5% (range: 0%–
9.5%; SD: 4.3) and 3% (range: 0%–9%; SD: 2.9) of the neoplastic
Sox10 -positive melanoma in situ and invasive melanoma cells,
respectively, were ciliated (figures 2, 3, and S2). Again, identical
results were obtained regardless of whether detyrosinated or
acetylated tubulin antibodies were utilized (figure S1). These
findings demonstrate a uniform loss of the primary cilium amongst
the neoplastic melanocytes of cutaneous melanoma in situ and
malignant melanoma and suggest that primary cilium assembly is
suppressed during the initiation of cutaneous melanoma.
Primary cilia can be either present or absent during progression
through interphase [4]. Thus, we were interested in learning
whether the observed loss of melanocytic primary cilia might be
due to ongoing cell cycle progression or instead, as an alternative
consequence of neoplastic transformation. To this end, we
performed Ki67 staining to compare the proliferative and ciliation
indices of the neoplastic melanocytes present in each case. Ki67 is
a protein that is present in the nucleus throughout the cell cycle,
including mitosis, but is absent during G0. Thus, were the loss of
the primary cilium to occur as a consequence of ongoing
proliferation we would expect the proportion of non-ciliated cells
to closely match the proportion of Ki67 -positive cells. In
agreement with prior reports documenting the highly variable
proliferation indices of melanocytic neoplasms [26–28], we found
average proliferative indices of 0.4% (range: 0%–3.2%; SD: 0.89),
8.4% (range: 2.4%–22.2%; SD: 7.0), and 37.4% (range: 11.6%–
43.4%; SD: 8.3) amongst our cases of melanocytic nevi, melanoma
in situ, and invasive melanoma, respectively (figures 4 and S2).
Therefore, and similar to that observed in pancreatic ductal
Figure 4. Cell cycle activity within melanocytic proliferations. See text for quantitation and further details. Immunostains and lesion types as
indicated. Scale bars, left panels: 100 mm. Scale bars, right panels: 50 mm.
doi:10.1371/journal.pone.0027410.g004
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invasive melanoma cells failed to ciliate, while as few as 2% were
actively progressing through the cell cycle. Thus, insofar as Ki67-
negative cells are not actively progressing through the cell cycle,
active cell cycle progression is unlikely to primarily account for the
loss of primary cilia observed in melanoma. However, it remains
formally possible that recent cell cycle activity could somehow
exert a residual negative influence on cilium assembly or
maintenance in melanoma cells.
Lastly, we were interested in learning whether the marked
reduction in primary cilia seen in primary cutaneous melanocytic
neoplasms might be seen in metastatic melanomas of known
cutaneous origin. As such, we examined a series of involved lymph
nodes from 8 patients with primary cutaneous invasive melanoma.
Similar to the in situ and invasive cutaneous melanoma cases
examined, we found that few metastatic melanocytes bore a cilium
(figure 5). While we noted that primary cilia were slightly more
apparent in metastatic lymph node deposits as compared to
primary melanomas (figure 5), we did not encounter a metastatic
deposit in which greater than 10% of the Sox10 positive cells were
ciliated. Thus, primary cilia are substantially depleted from
melanoma cells at all stages of cutaneous melanoma development
and progression.
Discussion
This study adds an additional chapter to the growing literature
describing the fate and function of primary cilia in cancer
development. In this study, we determined that primary cilia are
strikingly depleted during the development of cutaneous melano-
ma. By costaining for centriolar proteins and modified tubulins of
the ciliary axoneme we have found that, while primary cilia are
assembled by nearly all melanocytes contained within cutaneous
melanocytic nevi, they are lost from the vast majority of those
associated with cutaneous melanoma in situ, invasive melanoma,
and metastatic melanoma of dermal origin. Moreover, insofar as
at least 90% of the neoplastic melanocytes present in any single
lesion studied here were not ciliated while only 2%–43% were
actively progressing through the cell cycle as determined by Ki67
immunostaining, ongoing cell cycle progression does not account
for the loss of the primary cilium during melanomagenesis.
However, it remains formally possible that recent cell cycle activity
may somehow exert a residual negative influence on cilium
assembly or maintenance in melanoma cells.
Our findings provide an interesting parallel between pancreatic
adenocarcinoma development and melanoma with regard to the
ciliation status of in situ and malignant cell types and demonstrate
clear differences between cutaneous melanocytic nevi and
melanoma. However, several important questions remain.
One, at which stage during melanocyte transformation is the
primary cilium lost? The natural histories of cutaneous melano-
cytic nevi and melanoma in situ have proven difficult to
characterize and moreover, represent an area of ongoing
controversy. Because it remains possible that melanoma in situ
undergo a transient ciliated phase, it will be important to examine
a larger case series of cutaneous nevi and melanoma in situ in
order to determine whether ciliated melanoma in situ or unciliated
cutaneous nevi occur. Such studies would help determine whether
assays of primary cilium abundance may be developed and
ultimately applied to the early diagnosis of melanoma.
Two, while we have examined typical cutaneous melanocytic
nevi and melanoma, the more diagnostically challenging melano-
cytic proliferations include those with with ambiguous histopath-
ological features. These lesions are of particular interest with
regard to their ciliation status because they exhibit unpredictable
malignant potential. Therefore, we are currently working to
Figure 5. Metastatic melanoma cells of cutaneous origin frequently fail to possess a primary cilium. Immunostaining as indicated. Four
separate lymph node metastases of distinct morphologies from 4 separate patients are shown. Insets show ciliated or unciliated centrioles of Sox10
positive metastatic melanoma cells. Scale bars: 50 mm.
doi:10.1371/journal.pone.0027410.g005
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between primary cilia, dysplasia, and clinical outcome in the
setting of these lesions.
From a biological perspective, the implications of this study are
less clear but certainly raise interesting questions regarding the
initiation and progression of cutaneous melanoma. While biallelic
deletion of genes required for the assembly and function of
primary cilia dysregulates pathways important in cancer develop-
ment [3] and can modify the tumorigenic potency of hedgehog
pathway mutations [9,10], the relationship between the primary
cilium and the development of cancers not bearing hedgehog
mutations is unclear. In this regard, it is interesting that pancreatic
carcinoma and cutaneous melanoma thus far appear to exhibit
analogous patterns of cilium depletion during their development.
While pancreatic carcinoma and cutaneous melanoma are of
highly divergent embryologic origin, both are most frequently
associated with mutations inducing constitutive Ras pathway
activation and both are associated with frequent loss of function
mutations or epigenetic silencing of the p16 tumor suppressor. It is
likely that comparative analyses of these embryologically divergent
cancers may hasten the discovery of the mechanisms by which
cilium assembly is suppressed during their development and the
isolation of key oncogenic or tumor suppressive functions of
primary cilia.
Overall, while additional studies will be necessary to firmly
establish diagnostic and biological roles for primary cilia in
melanomagenesis, this study demonstrates that primary cilia are
depleted from cutaneous melanoma in situ, invasive melanoma,
and metastatic cutaneous melanoma cells and places the
widespread loss of an important regulator of oncogenic signaling
at an early phase of melanoma development.
Materials and Methods
Clinical Samples
All clinical samples were procured according to a protocol
approved by the Stanford University Research Compliance Office
Human Subjects Research Compliance Panel (FWA 00000935)
from the archives of the Stanford Department of Pathology. All
patient information associated with this study was obtained in de-
identified format and, as such, study-specific patient consent was
not obtained. All cases carried a prior pathological diagnosis
rendered by a board-certified dermatopathologist and were
verified histologically by J.K. and S.D.
Microscopy
7 mm-thick sections were cut, deparaffinized in xylene, rehy-
drated though graded ethanol dilutions, and subjected to
hematoxylin and eosin staining according to standard procedures.
Immunostaining was performed as described [6], with acetylated
tubulin (Sigma), detyrosinated tubulin (Covance), gamma tubulin
(Sigma), CP100 (gift from B.Dynlacht), Sox 10 (Santa Cruz
Biotechnology), and Ki67 (AbCam) antibodies used at 1:2000,
1:500, 1:200, 1:200, 1:200, and 1:200, respectively. Alexafluor
488, 594, and 647 chicken anti -mouse, -rabbit, and -goat
antibodies were used as secondary antibodies at a concentration of
1:300 each. Slides were then mounted using PermaFluor
mounting medium (Thermo) and stored at room temperature.
Imaging was performed as described in ‘‘Results’’ using a Zeiss
LSM META confocal and an Olympus BX series upright
fluorescence microscope.
Supporting Information
Figure S1 Detyrosinated tubulin antibodies show the
same pattern of cilium loss in neoplastic melanocytes as
do acetylated tubulin antibodies. Immunostaining and lesion
types as shown. Scale bars: 20 mm.
(TIF)
Figure S2 Proliferative indices do not fully account for
the loss of the primary cilium amongst neoplastic
melanocytes. (L) Average ciliation indices of melanocytic
proliferations expressed as the percent of lesional melanocytes
that are ciliated. (R) Average Ki67 proliferation indices of
melanocytic proliferations expressed as the percent of lesional
melanocytes that exhibit nuclear Ki67 immunoreactivity. Error
bars: Standard deviation of mean.
(JPG)
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